These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
568 related articles for article (PubMed ID: 31430555)
1. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555 [TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187 [TBL] [Abstract][Full Text] [Related]
3. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Gide TN; Wilmott JS; Scolyer RA; Long GV Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120 [TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Cousin S; Italiano A Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397 [TBL] [Abstract][Full Text] [Related]
5. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Maxwell R; Jackson CM; Lim M Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997 [TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034 [TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Xia Y; Medeiros LJ; Young KH Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946 [TBL] [Abstract][Full Text] [Related]
8. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. Olbryt M; Rajczykowski M; Widłak W Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213 [TBL] [Abstract][Full Text] [Related]
9. Future directions for checkpoint inhibition in melanoma. Hamid O Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805 [No Abstract] [Full Text] [Related]
10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H Front Immunol; 2018; 9():1878. PubMed ID: 30158932 [TBL] [Abstract][Full Text] [Related]
11. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757 [TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Organ Transplant Patients. Kittai AS; Oldham H; Cetnar J; Taylor M J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in the treatment of advanced urothelial cancer. Lundgren KT; Farina MS; Bellmunt J Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint therapy in liver cancer. Xu F; Jin T; Zhu Y; Dai C J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754 [TBL] [Abstract][Full Text] [Related]
16. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Qin S; Xu L; Yi M; Yu S; Wu K; Luo S Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Carreau NA; Pavlick AC Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646 [TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
19. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? Warner AB; Postow MA Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to Immune Checkpoint Blockade. Liu D; Jenkins RW; Sullivan RJ Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]